Reaffirmed: Consort Medical (LON:CSRT) “Buy” Rating Reconfirmed by Analysts at Investec Securities; GBX 1033.00 Target in Place


Consort Medical (LON:CSRT) Rating Reaffirmed

They currently have a GBX 1033.00 TP on Consort Medical (LON:CSRT). The target price by Investec Securities would suggest a potential upside of 1.77% from the company’s previous stock close. This has been released in a comprehensive report on 3 December.

From a total of 5 analysts covering Consort Medical PLC (LON:CSRT) stock, 6 rate it a ”Buy”, 0 a “Sell”, and 1 a ”Hold”. This means that 86% of the ratings are positive. The highest target price is GBX 1054 while the lowest target price is GBX 760. The mean of all analyst targets is GBX 961 with a -2.62% below today’s (GBX 1048) stock price. Consort Medical PLC was the topic of 2 analyst reports since August 20, 2015 according to the firm StockzIntelligence Inc. Canaccord Genuity maintained shares on November 3 with “Buy” rating.

The stock increased 3.87% or GBX 39 on December 3, striking GBX 1048. Approximately 63,662 shares of stock traded hands or 28.66% up from the average. Consort Medical plc (LON:CSRT) has risen 9.73% since May 6, 2015 and is uptrending. It has outperformed by 10.02% the S&P500.

Reaffirmed: Consort Medical (LON:CSRT)

Consort Medical plc is a contract development and manufacturing organization . The company has a market cap of 514.89 million GBP. The Firm is engaged in providing delivery technologies, formulation and manufacturing solutions for drugs. It has 46.36 P/E ratio. The Firm operates through two divisions: Bespak and Aesica.